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Background: Brain metastasis from breast cancer poses a major clinical challenge. Integrins play a role in
regulating adhesion, growth, motility, and survival, and have been shown to be critical for metastatic growth in
the brain in preclinical models. Cilengitide, an αvβ3/αvβ5 integrin inhibitor, has previously been studied as an
anti-cancer drug in various tumor types. Previous studies have shown additive effects of cilengitide and
radiation in lung cancer and glioblastoma cell lines. The ability of cilengitide to enhance the effects of radiation
was examined preclinically in the setting of breast cancer to assess its possible efficacy in the setting of brain
metastasis from breast cancer.
Methods: Our panel of breast cells was composed of four cell lines: T-47D (ER/PR+, Her2-, luminal A), MCF-7
(ER/PR+, Her2-, luminal A), MDA-MB-231 (TNBC, basal B), MDA-MB-468 (TNBC, basal A). The presence of
cilengitide targets, β3 and β5 integrin, was first determined. Cell detachment was determined by cell counting,
cell proliferation was determined by MTS proliferation assay, and apoptosis was measured by Annexin V
staining and flow cytometry. The efficacy of cilengitide treatment alone was analyzed, followed by assessment
of combined cilengitide and radiation treatment. Integrin β3 knockdown was performed, followed by
cilengitide and radiation treatment to test for incomplete target inhibition by cilengitide, in high β3
expressing cells.
Results: We observed that all cell lines examined expressed both β3 and β5 integrin and that cilengitide was
able to induce cell detachment and reduced proliferation in our panel. Annexin V assays revealed that a
portion of these effects was due to cilengitide-induced apoptosis. Combined treatment with cilengitide and
radiation served to further reduce proliferation compared to either treatment alone. Following β3 integrin
knockdown, radiosensitization in combination with cilengitide was observed in a previously non-responsive
cell line (MDA-MB-231). Clonogenic assays suggested little radiosensitization effects of cilengitide.
Conclusions: Cilengitide appears to enhance radiation response in preclinical models of breast cancer. These
data suggest that the combination of radiation therapy and cilengitide may prove to be effective where
radiation is utilized for the treatment of gross disease in breast cancer, such as in the setting of brain metastasis.
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Brain metastasis from breast cancer occurs in approxi-
mately 5% of patients overall, and in 10-16% of patients
with metastatic disease [1]. Incidence is thought to be on
the rise, as systemic therapy advances lead to better local
tumor control and improved survival. Current treatments
for these metastases include whole brain radiotherapy,
surgery, stereotactic radiosurgery, and chemotherapy [2].
Outcomes for these patients are poor with median sur-
vivals ranging from 3.4-25.3 months based on the Graded
Prognostic Assessment (GPA) [3]. Radiation is commonly
used in the treatment of brain metastasis from breast can-
cer, where there can be gross disease present in the brain.
Given that a significant percentage of these patients suc-
cumb to their metastatic disease and demonstrate local
progression of their disease in the brain, we sought to in-
vestigate agents that may demonstrate additive or syner-
gistic effects with radiation in the setting of breast cancer.
Integrins play a role in regulating cell-extracellular matrix
interactions as well as cell signaling pathways that regulate
adhesion, growth, motility, and survival [4]. Integrins are
expressed on endothelial cells, and play an important role
in angiogenesis [5], but have also been identified on a num-
ber of cancer cell types [6-8]. αVβ3 integrins specifically have
been identified to play a direct role in tumor cell growth as
well as invasion and metastasis [9,10]. αVβ3 integrins
were shown to be critical for metastatic growth of breast
cancer cells in the brain [11]. Therefore, we further examined
targeting integrin signaling in combination with radiation.
Cilengitide is a cyclic RGD containing pentapeptide that
targets αVβ3 and αVβ5 integrins [12]. This inhibitor has
been shown to block glioma cell growth via cell detach-
ment and induction of apoptosis in an in vitro model [13].
In vivo, cilengitide has been shown to inhibit metastatic
bone colonization by the breast cancer cell line MDA-
MB-231 [14].
In the context of radiation therapy, combination treat-
ment with cilengitide has been shown to radiosensitize
lung cancer cell lines [15], with lung cancer representing
the tumor site with the highest incidence of metastasis to
the brain [1]. Combination therapy of cilengitide and
radioimmunotherapy with an L6 antigen targeting anti-
body conjugated with the beta-emitter 90Y has shown to
improve outcomes of primary breast tumors in a xenograft
model of breast cancer [16]. The combination of cilengitide
and external beam radiotherapy has yet to be studied in the
context of breast cancer.
We therefore set out to determine if a combination ther-
apy of cilengitide and radiation could be of benefit for
breast cancer brain metastases patients. To this end we
tested the effect of cilengitide in combination with radi-
ation in a panel of breast cancer cell lines, among them
cell lines that have previously been used to study brain
metastases from breast cancer.Methods
Cell culture and drug treatment
T-47D (ER/PR+, Her2-, luminal A), MCF-7 (ER/PR+,
Her2-, luminal A), MDA-MB-231 (TNBC, basal B), MDA-
MB-468 (TNBC, basal A) cell lines cells were purchased
from ATCC. T-47D (RPMI-1640 medium supplemented
with 10% fetal bovine serum, 1% penicillin/streptomycin,
and 0.2Units/ml bovine insulin) and MCF-7 (Eagle’s mini-
mum essential medium supplemented with 10% fetal bo-
vine serum, 1% penicillin/streptomycin, and 0.01 mg/ml
bovine insulin) cell lines were maintained at 37°C in a
5% CO2 atmosphere. MDA-MB-231 and MDA-MB-468
(Leibovitz’s L-15 medium supplemented with 10% fetal bo-
vine serum and 1% penicillin/streptomycin) cell lines were
maintained at 37°C in an air atmosphere. Cilengitide was
acquired through the Cancer Therapy Evaluation Program
(CTEP) from Merck. Irradiation was performed using a RS-
2000 Biological Irradiator (Rad-Source) with 160 kV x-rays
with a 0.3 mm copper filter in place at a dose rate of approx.
1.2 Gy/min. All statistical comparisons were performed
using repeated measures ANOVA with a Tukey’s multiple
comparison test. All research (non-human subject research,
non-animal research) was done in accordance with institu-
tional guidelines.
Western blotting
Untreated cells were washed and trypsinized, followed by
pelleting and freezing at -80°C. Upon thawing cells pellets
were resuspended in RIPA lysis buffer (50mM Tris–HCl,
pH 8.0, with 150mM sodium chloride, 1.0% Igepal CA-
630 (NP-40), 0.5% sodium deoxycholate, and 0.1% so-
dium dodecyl sulfate) supplemented with the addition
of Protease inhibitor cocktail (Sigma), phosphatase in-
hibitor cocktail 1 (Sigma), phosphatase inhibitor cocktail 2
(Sigma), and phenylmethylsulfonyl fluoride (Sigma). Pro-
tein concentration was determined with a BCA Protein
Assay kit (Thermo Scientific) and 50ug was loaded per
well in a 4-20% TGE precast gel (Bio-rad), followed by
transfer to PVDF membranes. Membranes were blocked
using 5% bovine serum albumin in TBS-T, followed by
overnight incubation at 4°C with primary antibody solu-
tion for β3 or β5 Integrin (1:1000, cell signaling). Blots
were incubated with anti-rabbit secondary antibody
(1:2000, cell signaling) was at RT for 1 hr. Blots were then
developed using Immobilon Western Chemiluminescent
HRP Substrate (Millipore) in the VersaDoc imaging sys-
tem (Bio-rad).
Flow cytometry - apoptosis
Apoptosis assays were performed using the Alexa Fluor®
488 Annexin V/Dead Cell Apoptosis Kit (Life Technolo-
gies) according to the manufacturer’s instructions. Briefly,
cells were plated and allowed to attach overnight. The







Figure 1 Expression of β3 and β5 integrin in a panel of breast
cancer cell lines. Western Blot of T-47D, MCF-7, MDA-MB-231, and
MDA-MB-468 cell lines for β3 and β5 Integrin. β3 target is observed
in all cell lines, with MDA-MB-231 and MDA-MB-468 showing the
highest levels, while T-47D and MCF-7 cells showed a lower level of
expression. β5 target is observed in all cell lines, with T-47D showing
the highest levels, MCF-7 and MDA-MB-231 showing intermediate
levels, and MDA-MB-468 showing a lower level of expression.
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Apoptotic induction controls were treated with 16.6 uM
cisplatin 24 hours before staining. After 48 hours, cells
were harvested (floating and attached cells) and stained
according to manufacturer’s instructions. Single stained
and unstained controls were included. Flow cytometry was
performed on a BD Facs LSR II flow cytometer under guid-
ance from flow cytometry core staff. Samples were ana-
lyzed using Flow Jo software.
Clonogenic assay
All cell lines were trypsinized and counted, followed by di-
lution to appropriate levels. Cells were seeded in triplicate
in 2 ml growth media into 6-well tissue culture dishes and
allowed to attach overnight. The following morning, the
indicated doses of cilengitide were added to the cells. Ir-
radiation was performed at the indicated doses 1 hour
after drug treatment. Cells were then maintained at 37°C
in the appropriate atmosphere for 10 days to 1 month
until appropriate sized colonies had formed. Once col-
onies were visible, cells were stained in 0.5% crystal violet
in methanol for 2 hours. Colonies were counted with the
use of a dissecting microscope with a cutoff of 50 cells.
Dose enhancement ratios are reported for 37% cell
survival.
Cell counting
Cells were plated at 2 × 105 cells/well and allowed to attach.
Cell counting was performed following 1 hr treatment with
the indicated cilengitide doses. Detached cells were re-
moved and wells were washed with PBS. Remaining at-
tached cells were then trypsinized and diluted 1:2 with
trypan blue. Live cells were counted in duplicate using the
Nexelcom Cellometer Auto T4 cell counter (Nexelcom
Bioscience). Remaining cell viability was at least 95%.
MTS assay
Proliferation assays were performed using the CellTiter
Aqueous One Solution Cell Proliferation Assay (Promega)
according to modified manufacturer’s instructions. 2 × 104
cells/well were plated in 500 ml growth medium in tripli-
cate. Cells were treated at the indicated dose of cilengitide
on day 0. Control readings were measured on day 0 to
control for plating inaccuracies and cell metabolism differ-
ences. The CellTiter solution was diluted 1:6 and 240 ul/
well was added. Plates were incubated for 3 hrs at 37°C,
followed by removal of 100 ul of MTS solution. Absorb-
ance at 490 nm was obtained using a Mithras LB 940 plate
reader (Berthold Technologies). Treated cells were left for
96 hours and absorbencies were obtained as above. ITGB3
knockdowns were performed using ON-TARGET Plus
SMARTpool Human ITGB3 siRNA and Control Non-
Targeting siRNA. Cells were treated with 25 nM siRNA
for 48 hours before plating. Day 4 values were controlledto Day 0 values within each cell line. Values were also con-
trolled to untreated cell values and reported as % Cell Viabil-
ity compared to untreated cells. For the ITGB3 knockdown
experiments, normalization was performed against the un-
treated control cells for each group (Non-Targeting cells or
ITGB3 knockdown cells respectively).Results
Cilengitide target expression in breast cell lines
β3 and β5 integrins, found as dimers with αV integrins, are
the targets for the inhibitor cilengitide. αVβ3 integrin is
thought to represent the primary target, while αVβ5 is an
alternate target. We examined the breast cancer cell lines
T-47D, MCF-7, MDA-MB-231, and MDA-MB-468 for β3
and β5 integrin expression by western blot. As shown in
Figure 1, we detected both β3 and β5 integrin in all of our
cell lines (β3 integrin can be detected as possibly 3 different
bands of 97, 110, and 130 kDa). T-47D and MCF-7 cell
lines expressed β3 integrin at low levels, while MDA-MB-
231 and MDA-MB-468 cell lines expressed β3 integrin at
higher levels than the other two cell lines studied. β5 integ-
rin was most strongly expressed in T-47D cells, at inter-
mediate levels in MCF-7 and MDA-MB-231 cells, and only
very lowly expressed in MDA-MB-468 cells.
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Cell detachment
Once expression of the target of cilengitide was verified,
we assessed the effects of cilengitide treatment as a single
therapy in our panel of cell lines. Previous studies have
shown that cilengitide causes cell detachment in culture
[13,15]. The role of integrins in cell adhesion to uncoated
plastic dishes is probably related to serum vitronectin ad-
hering to the plastic [17]. We wanted to examine this cellu-
lar detachment in our panel of cell lines. Briefly cells were
treated with cilengitide (500 nM, 5 uM, and 20 uM) for 1
hour. Detached cells were then washed away with PBS,
and remaining attached cells were trypsinized and counted.
We observed that in most of our cell lines there was a dose
dependent effect of cilengitide on cell detachment. At the
highest dose tested (20 uM) T-47D cells showed the most
marked response, with almost complete detachment of
cells following 1 hour of treatment (Figure 2). MDA-MB-
468 cells showed little to no cell detachment at this early
timepoint, even at this highest dose. Both of the other cell
lines tested showed a moderate response to the 20 uM
dose, losing about 50% of plated cells (Figure 2). Most of





Figure 2 Cell detachment following 1 hr Cilengitide treatment. Cells w
attached cells were trypsinized and counted. A) T-47D cells showed a stron
cilengitide treatment. B) MCF-7 cells showed moderate cell detachment sim
cell detachment following this short exposure to cilengitide. Figures show
* = ≤ 0.05.opposed to dead. Cells treated for 1 hour with 20 uM
cilengitide to cause detachment, were then washed with
PBS and re-plated into a new cell culture dish. At least a
part of these washed cells were able to attach and grow
normally (data not shown). Cells left in cilengitide up to 96
hours remained detached (data not shown).
Growth inhibition
The same trends discussed above were observed in our
panel of cell lines in a longer term proliferation assay.
Breast cancer cell lines were plated, allowed to attach
overnight, and then treated the following morning with
varying doses of cilengitide (1 uM, 5 uM, 10 uM, and
20 uM). The cells were then allowed to grow for 96 hours
in the presence of cilengitide and cell viability was deter-
mined. As shown in Figure 3 the cell responses at 96
hours following cilengitide treatment are similar to the
early 1 hour detachment response. In this assay, T-47D
cells still showed the most marked response, with almost
complete cell loss compared to untreated cells at the
20 uM dose (Figure 3). MDA-MB-468 cells again showed
no response to cilengitide treatment, even at the 20 uM
dose. In this assay, MDA-MB-231 cells had a reducedD
B
*
ere treated with cilengitide for 1 hr, washed with PBS, and remaining
g dose response, with almost complete cell detachment at 20 uM
ilar to C) MDA-MB-231 cells. D) MDA-MB-468 cells showed little to no







Figure 3 MTS proliferation assay following prolonged cilengitide treatment. Cells were treated with Cilengitide for 96 hours, followed by
washing and addition of an MTS substrate. After 4 hour incubation, absorbance was read and cell viability as percent of control treated cells was
reported. A) T-47D cells show the most marked response, with little to no cell growth at the 20 uM cilengitide dose. B) MCF-7 cells show a
moderate growth delay. C) MDA-MB-231 cells also show a moderate growth delay. D) MDA-MB-468 cells show little to no growth delay
compared to controls at this 96 hour timepoint. Most cell lines showed a dose response to cilengitide (A-C) with only MDA-MB-468 cells
showing no effects. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.
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ment assay, showing only 25% reduction in cell proliferation
after 96 hours of cilengitide exposure compared to controls
as opposed to 50% of cells detached after 1 hour (Figures 2C
and 3C). On the other hand MCF7 cells showed a more no-
ticeable response, with nearly an 80% reduction in cell pro-
liferation compared to the 50% of cells lost after 1 hr of
treatment (Figures 2B and 3B). Overall these results are con-
sistent with the early cell detachment results. Cilengitide ap-
pears to have a significant effect, on both cell attachment
and cell growth, in our breast cancer cell lines.
Cilengitide induces apoptosis
To examine the mechanism by which cilengitide reduces
viability in our cells, we performed an apoptosis assay at an
intermediate timepoint (48 hours) following cilengitide
treatment. First, cilengitide treatment alone induced apop-
tosis in all cell lines except for the MDA-MB-468 cells, and
this apoptotic induction was dose dependent (Figure 4).
This pattern of cell line dependent cilengitide responsive-
ness is consistent with our earlier cell detachment results
(Figure 2) and cell proliferation data (Figure 3). In this
assay, we again observed that the most significant effects ofcilengitide occurred in the T-47D cell line. The late apop-
totic/dead (Q2) and early apoptotic (Q3) events were in-
creased from Q2 – 6.67%, Q3 – 7.69% in T-47D control
cells to Q2 – 19.0%, Q3 – 23.9% in cells treated with
20 uM of cilengitide. MCF-7 cells showed the next highest
response (control; Q2 – 2.25%, Q3 - 5.49% to 20 uM; Q2 –
17.7%, Q3 – 23.4%). MDA-MB-231 (control; Q2 – 1.67%,
Q3 – 6.36% to 20 uM; Q2 – 3.39%, Q3 – 13.6%) showed a
more moderate effect of cilengitide treatment in this assay.
MDA-MB-468 cells showed no response to cilengitide, as
in the other assays performed (control; Q2 – 2.43%, Q3 –
2.10% to 20 uM: Q2 – 2.85%, Q3 – 3.79%). Our findings in-
dicate that cilengitide is able to induce apoptosis and death
in some of our tested breast cancer cell lines when used as
a single treatment. This finding is in line with other reports
which indicate that cells detached by cilengitide treatment
go on to apoptose [13]. However, even in a cell line/
cilengitide dose combination (T-47D and 20 uM) where
100% of cells appear detached microscopically after one
hour (data not shown, compare to Figure 1) there are still
approximately 44% of live cells (Quadrant 4) at 48 hrs. It
was also observed in T-47D cells exposed to cilengitide for







Control          1uM              5uM            10uM            20uM
Figure 4 Cilengitide induces apoptosis in breast cell lines. Cells were treated for 48 hours with the reported cilengitide doses and then
harvested for Annexin V/PI staining and analysis by flow cytometry. T-47D cells showed the highest level of apoptotic/dead cells. MCF-7 cells
showed the next highest levels of apoptotic/dead cells, with levels very similar to T-47D cells. MDA-MB-231 cells show a moderate induction of
apoptosis. MDA-MB-468 cells show no apoptotic induction, which mirrors the cell detachment and proliferation assay results. Experiment was
performed three times with similar results. Figures are from a representative experiment.
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not all of the detached cells are dead or dying.Effects of cilengitide in combination with radiation
After characterizing the response of our cell lines to
cilengitide as a single therapy, we sought out to determine
if cilengitide could serve as a radiosensitizer. First, we
performed a proliferation assay (MTS) as discussed earlier
(Figure 3) with ionizing radiation (IR) added to the
cilengitide treatment groups. T-47D, MCF-7, and MDA-
MB-231 cells were treated at 4 Gy, while MDA-MB-468
cells were treated at 2 Gy. An initial test had shown that
MDA-MB-468 cells were especially sensitive in terms of
viability at 96 hours after IR with 4 Gy (data not shown).
All of the cell lines appeared to have reduced viability after
combination treatment of cilengitide and IR compared
to IR alone (Figure 5). For T-47D and MCF-7 cells those
differences were statistically significant, while for MDA-
MB-231 and MDA-MB-468 we observed only a trend to-
wards improved efficacy of the combination treatment.
Clonogenic assays showed only very minor increases in ra-
diosensitivity following cilengitide treatment in some of
the cell lines tested (Figure 6). These results indicate that
cilengitide is enhancing the effects of radiation in our
panel of cells, and that there may be an additive effect for
this combination treatment.It was observed that the least responsive cell lines in this
study were those with the highest levels of β3 and lowest
levels of β5 integrin target. The association of high expres-
sion levels of integrin β3 and poor response to cilengitide
in our small cell line panel suggests that integrin β3 is the
relevant cilengitide target. One possibility for these results
is that this target is not completely inhibited at the
cilengitide doses used. Since integrin β5 expression was
associated with responsive cell lines, we determined that
this target was likely being adequately inhibited by the
cilengitide doses studied. To examine if these cells were
unresponsive to cilengitide treatment due to incomplete
β3 blockade at tested treatment doses, β3 integrin was
knocked down in the MDA-MB-231 cell line. Approxi-
mately 50% knockdown was achieved in these cell lines
(Figure 7A). 48 hours following knockdown, cells were
plated and treated as in the above experiments. Figure 7B
shows that cells with reduced β3 integrin show enhanced
response to radiation and cilengitide combination treat-
ment, while previously they were minimally responsive to
cilengitide and radiation treatment (Figure 5).
Discussion
Brain metastases from breast cancer occur in 10-16% of
patients who eventually develop metastatic disease [1].
The advent of brain metastases often is a life altering event





Figure 5 MTS proliferation assay following prolonged cilengitide treatment in combination with ionizing radiation. Cells were treated in
the same manner as in Figure 3, with the addition that for the radiation groups, cells were treated with the indicated dose of IR following 1 hr of
cilengitide treatment. All four cell lines show a combination effect where cilengitide in combination with radiation has an enhanced growth
delay effect when compared to IR alone treated cells. A) T-47D cells show this combination effect at lower doses of cilengitide than other cells
lines. B) MCF-7 cells show an improvement over radiation alone with cilengitide combination. C) MDA-MB-231 cells show a trend toward an
enhanced effect of cilengitide in combination with IR treatment. D) MDA-MB-468 cells also show only a trend toward increased growth delay in
the combination groups versus the radiation alone group. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.
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tients with brain metastases are poor with median survival
times ranging from 3.4-25.3 months depending on GPA
[3]. There is an urgent need for novel therapeutic ap-
proaches to improve outcomes in this patient population.
In this study we present our findings suggesting cilengitide
treatment can induce cellular detachment and apoptosis,
and reduce proliferation in a panel of breast cancer cell
lines. While this is, to our knowledge, the first report to de-
scribe cilengitide effects in combination with radiation in a
panel of breast cancer cell lines our findings are consistent
with previous reports describing induction of apoptosis, re-
duced proliferation, and cellular detachment after cilengitide
treatment in glioma [13] and lung cancer [15] models.
The primary target of cilengitide is αvβ3 integrin. Integrin
expression on tumor cells plays a role in activating many of
the major cell survival pathways including ERK and PI3K
signaling [18]. These pathways are known to lead to in-
creased tumor cell proliferation, migration, and resistance
to apoptosis [19]. Furthermore inhibition of those pathwayscan result in radiosensitizing effects in many cancer cell
lines [20]. Therefore, we speculate that these pathways
could mediate the treatment effects in breast cancer cell
lines as well, and it is not surprising that the integrin inhibi-
tor cilengitide has anti-tumor activity in lung and glioma
models or in breast cancer models as here presented.
The magnitude of cilengitide effects on breast cancer cell
lines, however, was fairly heterogeneous among the cell lines
tested. Given that only four cell lines were tested no defini-
tive conclusions can be drawn at this time as to which
breast cancer brain metastases patient subpopulations might
derive the most benefit from cilengitide containing treat-
ment regimens. It appeared that cell lines that are ER/PR
positive and Her2 negative or cell lines with lower expres-
sion levels of integrin β3 had the most significant response
to cilengitide treatment in this study. Experimentally redu-
cing the expression of integrin β3 in a cell line with high in-
tegrin β3 expression (MDA-MB-231) resulted in increased
efficacy of cilengitide and radiation. Given that integrin β3
knockdown can sensitize cells to the tested cilengitide doses,
ADC
B
Figure 6 Clonogenic assay in combination with cilengitide in breast cell lines. Clonogenic assays were performed with our panel of breast
cell lines. Cells were plated at specific cell numbers and treated with indicated doses of cilengitide. After 1 hr of treatment, cells were irradiated and
then incubated for up to 4 weeks to allow colony formation. Cells were then stained and counted. All four cell lines show small dose enhancement
ratios with the addition of cilengitide, indicating no or very little radiosensitization effects. A) T-47D (DER – 1.21), B) MCF-7 (DER – 1.25), C) MDA-MB-










Figure 7 MTS proliferation assay following ITGB3 knockdown in MDA-MB-231 cells. Cells were treated with 25nM siRNA (either NT or
ITGB3) for 48 hours before being treated in the same manner as described in Figure 5. A) Target knockdown was confirmed via western blot.
B) Cells treated with NT siRNA showed a similar pattern to previous results, while cells treated with ITGB3 siRNA showed a pronounced
radiosensitization in combination with cilengitide treatment. NT untreated controls and ITGB3 untreated controls were used for normalization
within their respective groups. The ratio of ITGB3 knockdown/NT treated cell viability cell viability at 96 hours is 0.935. Figures show Mean ± SEM
and represent the average of three experiments. * = ≤ 0.05.
Lautenschlaeger et al. Radiation Oncology 2013, 8:246 Page 8 of 10
http://www.ro-journal.com/content/8/1/246
Lautenschlaeger et al. Radiation Oncology 2013, 8:246 Page 9 of 10
http://www.ro-journal.com/content/8/1/246it appears that this target is not completely inhibited in cell
lines with high expression of integrin β3. While it is still
possible that integrin β5 inhibition is responsible for the en-
hanced response seen in the T-47D or MCF-7 cell lines,
these results indicate that at least a portion of the cilengitide
resistance in our other cell lines is due to the high levels of
integrin β3 expression observed. While the results of our
proliferation assays have shown clear statistical benefit of
combination therapy compared to either therapy alone in
some breast cell lines, our clonogenic data shows little to
no formal radiosensitization effect. Our results indicate
a more significant benefit of combined radiation and
cilengitide treatment at earlier timepoints compared to the
long term results of the clonogenic assays. This difference
could well be due to the different timepoints tested. How-
ever, the performed normalization of the radiated arm to
the cilengitide alone treated cells likely contributes to this
observed difference as well. Our data however is similar
to reports using glioma models [21] where modest radio-
sensitizing effects of cilengitide were found. Previously it has
been reported that cilengitide and radiation have additive ef-
fects in glioma cell lines [22]. Our data indicate a similar
additive nature of combination cilengitide and radiation
therapy in breast cancer cell lines, rather than a synergistic
or supra-additive effect. These results are more limited in
scope when compared to more significant radiosensitizing
effects of cilengitide reported in NSCLC models [15]. The
underlying reasons for the differences in potency of
cilengitide as a radiosensitizer in different cancers remain to
be identified and is subject to further studies. Despite the
differences in efficacy seen comparing our assays, combined
cilengitide and radiation treatment appeared to be beneficial
for most of the tested breast cancer cell lines.
In summary, our data suggest cilengitide treatment has
anti-tumor activity in breast cancer cell line models, and
that combination treatment with radiation appears to affect
cells more than either treatment alone. Given that some of
the cell lines used in our study have previously been used
as breast cancer brain metastases models [23], and that
cilengitide potentially can achieve therapeutically relevant
concentrations in the brain, we conclude that combined
cilengitide and radiation treatment could be a promising
therapeutic strategy for a subset of breast cancer brain me-
tastases patients.
Conclusions
Combined cilengitide and radiation therapy appears to be
more efficacious than either treatment alone in breast can-
cer cell lines. This study, along with previous work high-
lights the promise of cilengitide therapy in combination
with radiation. Based on the ability of cilengitide to accu-
mulate in the brain combination treatment of cilengitide
and radiation could be beneficial clinically for a subset of
breast cancer brain metastases patients.Abbreviations
GPA: Graded prognostic assessment; CTEP: Cancer therapy evaluation
Program; IR: Ionizing radiation.
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